HIV Diagnostics Market

HIV Diagnostics Market Size, Market Forecast and Outlook By FMI

The hiv diagnostics market was valued at USD 3.80 billion in 2025, projected to reach USD 4.08 billion in 2026, and is forecast to expand to USD 8.42 billion by 2036 at a 7.50% CAGR. As per FMI, the incremental opportunity across the forecast period amounts to USD 4.33 billion, reflecting a steady expansion trajectory shaped by evolving end-use requirements and shifting procurement patterns across global supply chains.

Expanding global HIV testing coverage targets, decentralized point-of-care testing deployment, and growing viral load monitoring adoption are driving procurement growth for HIV diagnostic products across laboratories, hospitals, and community testing settings. WHO-recommended test-and-treat strategies that mandate routine viral load surveillance for all patients on antiretroviral therapy are substantially expanding the per-patient diagnostic consumption footprint beyond initial screening. FMI is of the opinion that the consumables segment commands the majority of revenue share as recurring reagent and test kit procurement outpaces one-time instrument capital expenditure across both centralized laboratory and decentralized point-of-care testing platforms.

Summary of HIV Diagnostics Market

• The market is estimated at USD 3.80 billion in 2025.
• The market is projected to reach USD 8.42 billion by 2036.
• The market is expected to grow at a CAGR of 7.50% from 2026 to 2036.
• The forecast period represents an incremental opportunity of USD 4.33 billion.
• Consumables lead by product segment with a 55.6% share in 2026.
• Antibody tests dominate by test type with a 42.5% share in 2026.
• The market is driven by WHO test-and-treat strategies and expansion of viral load monitoring programs.
• Product scope includes consumables, instruments, and diagnostic software for HIV detection and monitoring.
• South Korea (8.0%), Canada (5.5%), and Indonesia (5.3%) are among the fastest-growing markets.
• Key companies in the market include Siemens Healthineers, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Bristol-Myers Squibb Company, Janssen Global Services, LLC, Gilead Sciences, Inc., Merck & Co. Inc., QIAGEN, Apogee Flow Systems, and Point Care.

HIV Diagnostics Market Key Takeaways

Metric	Details
Industry Size (2026)	USD 4.08 Billion
Industry Value (2036)	USD 8.42 Billion
CAGR (2026-2036)	7.50%

Source: Future Market Insights, 2026

Regional demand for HIV diagnostics reflects the geographic distribution of HIV prevalence, testing coverage targets, and diagnostic infrastructure investment. South Korea at 8.0% CAGR, Canada at 5.5% CAGR, Indonesia at 5.3% CAGR, France at 5.2% CAGR, Argentina at 4.8% CAGR, Poland at 4.6% CAGR, GCC Countries at 3.9% CAGR. China leads growth through expanded national HIV screening programs and centralized laboratory network modernization.

India follows on the strength of national AIDS control program procurement and decentralized testing deployment across district hospitals. Germany sustains growth through precision diagnostic laboratory standards and surveillance testing requirements. France and the United Kingdom maintain growth through routine screening mandates and viral load monitoring adoption. The United States advances through CDC-recommended routine screening expansion and fourth-generation combination test deployment. Brazil registers steady growth tied to national HIV testing program procurement and decentralized community testing initiatives.

Based on FMI's report, the hiv diagnostics market is expected to create an incremental opportunity of USD 4.33 billion between 2026 and 2036. FMI analysts project that end-use procurement patterns and regional supply chain dynamics will shape the distribution of this opportunity across segments and geographies.

HIV Diagnostics Market Definition

HIV diagnostics encompass in-vitro diagnostic products used for the detection, confirmation, and monitoring of human immunodeficiency virus infection. Product categories include consumables (reagent kits, rapid diagnostic tests, self-test kits), instruments (laboratory analyzers, point-of-care testing platforms), and software and services. Test types span antibody detection, antigen/antibody combination assays, viral load quantification, and CD4 cell count monitoring. These products are deployed across diagnostic laboratories, hospitals, community health centers, and self-testing programs.

Future Market Insights analysis captures the complete addressable consumption base across all major producing and consuming regions, covering the forecast period from 2026 to 2036.

HIV Diagnostics Market Inclusions

Market scope includes HIV diagnostic consumables, instruments, and software/services across antibody, viral load, CD4, and other test types for diagnostic laboratories, hospitals, and other end-user settings. The assessment covers global and regional market sizes, forecast period 2026 to 2036, and segment breakdowns by product, test type, end user, and region.

HIV Diagnostics Market Exclusions

The scope excludes antiretroviral therapy drugs, pre-exposure prophylaxis products, HIV vaccine candidates, and non-diagnostic laboratory equipment. Blood bank screening systems dedicated exclusively to transfusion safety are not included.

HIV Diagnostics Market Research Methodology

• Primary Research: Analysts engaged with procurement managers, clinical specialists, and distribution channel executives to map the decision gates and compliance thresholds shaping product adoption.
• Desk Research: Data collection aggregated regulatory filings, clinical guidelines, trade body publications, and company financial disclosures across all major producing and consuming regions.
• Market-Sizing and Forecasting: Baseline values derive from a bottom-up aggregation of product shipment volumes and utilization data, applying region-specific adoption growth curves to project demand velocity through 2036.
• Data Validation and Update Cycle: Projections are tested against publicly reported industry statistics, clinical data, and company guidance. The model is updated quarterly to reflect market structure changes.

Key Industry Highlights

Growing Prevalence of HIV/Aids to Drive the Market

Most infected HIV patients are between the age group of 15 to 49 and the prevalence rate has been stable since 2001. The overall number of HIV positive patients has increased despite the stabilization.

A rise from 31.5 million in 2010 to 3.8 million individuals in 2026 is recorded. This rise attributes to the longevity of new infections and increased life expectancy of infected population. Among the 3.8 million infected 1.5 million were minors and rest adults.

HIV detection over the years has been greatly improved primarily attributed by the expanded capacity of HIV testing capabilities. Yet nearly 14% of HIV-positive patients, are unaware of their status. This gap highlights the critical need for more widely available and easily accessible diagnostic tools to find instances that go untreated, support early intervention, and stop the virus.8;s spread.

The market for HIV diagnostics is expected to develop in light of these factors. The need for cutting-edge diagnostic technology is driven by the ongoing increase in the number of HIV positive individuals as well as the significant percentage of cases that remain undetected.

Raising awareness and promoting testing are crucial for controlling the epidemic as well as managing individual health outcomes and public health activities. In order to meet these objectives, guarantee prompt diagnosis, and enable efficient treatment plans, it is imperative that cutting-edge diagnostic technologies be continuously developed and implemented.

Growing Demand and Market Expansion for HIV Diagnostics

The increasing demand for HIV diagnostics is highly attributed to identifying key virus strains, which is the causative agent of acquired immunodeficiency syndrome (AIDS). Primary samples of serum, saliva, or urine are used in HIV testing to determine the presence of the virus.

These tests are crucial for detecting HIV-related antibodies, antigens, and RNA, allowing for early diagnosis and efficient treatment of the illness.

Rise in awareness of HIV, increased efforts towards privacy for testing, improved accessibility to tests and counseling services are some of the key factors that contribute to the expansion of this market.

Costing Related to HIV Diagnostics may Restrict HIV Diagnostics Market Growth

The market for HIV diagnostics is being held back significantly by the high expenses of nucleic acid testing (NAT).

Although incredibly precise and able to diagnose HIV at an early stage, NAT requires expensive technology and equipment to acquire and maintain. NAT test requires high cost and quality of consumables and specialized trained staff that contribute to the high cost of this test.

This prevents the medical facilities to adopt and regularly use NAT for HIV diagnosis, particularly those with tight finances. This expensive obstacle prevents NAT from being widely implemented, which in turn prevents this cutting-edge diagnostic technique from being more widely available and accessible.

The HIV diagnostics market is further constrained by the absence of NAT requirements in developing countries, in addition to the high costs. In most middle and low income countries the guidelines and regulations for NATs is not significant this results in healthcare systems to adopt less accurate testing modes due to cost constraints.

Healthcare providers have less incentive to invest in NAT technology when governments and international health organizations do not provide mandates or financial support.

As a result, efforts to control and reduce the transmission of the virus are negatively impacted, since undeveloped countries continue to have greater percentages of HIV cases that go undiagnosed or are discovered later in life.

2021 to 2025 Global HIV Diagnostics Sales Outlook Compared to Demand Forecast from 2026 to 2036

The global HIV diagnostics industry recorded a CAGR of 5.3% during the historical period between 2021 and 2025. The growth of HIV diagnostics industry was positive as it reached a value of USD 3,253.2 million in 2025 from USD 2,477.7 billion in 2021.

The demand for HIV diagnostics is expected to increase because they offer quick and easy tests with visual results, and home sample collection that can be used by both healthcare workers and individuals at home. These benefits are driving the sales of HIV diagnostic methods and helping the market grow.

The rapid adoption of point-of-care (POC) tools and tests globally will also indirectly drive the sales of HIV diagnostic POC products. Rapid tests are simple and are affordable making them top choice for most patients. Furthermore, use of POC at home tests is becoming more popular due to the choice of privacy and comfort of at-home testing.

With PoC HIV testing, counseling and screening happen at the same time while the patient is still in the lab. If needed, confirmation tests are done on the spot. Since both pre-test and post-test counseling are provided during the visit, patients do not need to return for their results, making it a very convenient option. Because of these factors, the demand for HIV diagnostics is expected to grow significantly in the coming years.

Market Concentration

Leaders in the industry with a revenue over USD 100 million, or 72.4% of the worldwide market, are referred to as Tier 1 firms. The top players in the HIV diagnostics industry are renowned for their broad product offers and high manufacturing capacities.

These industry experts have a solid clientele, a wealth of knowledge spanning several geographic areas, and proficiency in producing and renovating a wide range of package styles.

In order to guarantee the highest quality, they provide a wide range of goods, including production, recycling, and refurbishing, all of which adhere to the most recent legal and technological criteria. Abbott Laboratories, Thermo-Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., and Merck & Co. Inc. are significant participants in the upper segment of the market.

Medium-sized companies in the HIV testing market, known as Tier 2 companies, make between USD 50 to USD 100 million in sales. They're significant in certain areas and have about a quarter of the market. These companies are well-known globally and understand the market well.

They have good technology and follow the rules, but they might not have the latest technology or be present everywhere. Some important Tier 2 players include Bristol-Myers Squibb Company, Danaher Corporation, Gilead Sciences, Inc., and Zyomtronix, Inc.

Tier 3 comprises most small businesses with less than USD 50 million in revenue that operate locally and cater to specific markets. These businesses are categorized in the tier 3 share sector because they are particularly focused on meeting the needs of the local market.

Their geographical reach is restricted and they operate on a small basis. In this particular context, Tier 3 is classified as an unorganized market, which refers to an industry that lacks considerable structure and formalization in contrast to its organized rivals.

Country-wise Insights

The section below covers the industry analysis for the HIV diagnostics market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided.

The United States is anticipated to remain at the forefront in North America, with a value share of 82.5% through 2036. In Asia Pacific, South Korea is projected to witness a CAGR of 8.0% by 2036.

Countries	Value CAGR (2026 to 2036)
Canada	5.5%
Argentina	4.8%
France	5.2%
Poland	4.6%
Indonesia	5.3%
South Korea	8.0%
GCC Countries	3.9%

Source: FMI analysis based on primary research and proprietary forecasting model

Growing Demand of the HIV Diagnostics Boosting Sales in Germany

Germany’s HIV diagnostics market is poised to exhibit a CAGR of 3.2% between 2026 and 2036. Currently, Germany holds the maximum share in the European Union, and this trend is expected to continue during the forecast period.

Federal Ministry of Health in Germany has taken proactive steps towards combating HIV, focusing on early prevention, testing, and treatment. Central to their strategy are public initiatives that ensure comprehensive health coverage and widespread awareness.

Germany’s healthcare system stands out for its free and confidential HIV testing services, which are available to everyone, including high-risk groups and marginalized communities.

Prominent academic institutions collaborate and works together to provide an excellent environment in which cutting-edge instruments and treatments are continuously being created and enhanced.

In view of this solid collaboration among the academic institutions, business, and medical experts, Germany will firmly be at the top in the area of research on HIV and the medical application that goes with it.

Germany has made huge contributions to fighting the virus at international levels and has improved the quality of life for those living with HIV through innovative research and offering robust healthcare.

Increasing Prevalence of HIV and Government Initiatives in the United States Fueling Demand in the USA

The market of HIV diagnostics in the USA is expected to grow at a CAGR of 3.2% from 2026 to 2036. According to the National Library of Medicine, USA has a comparatively high HIV prevalence when compared to other countries.

The USA government spends hundreds of millions of dollars funding research for HIV, almost solely through the NIH, which administers many different research programs. These programs fund a broad portfolio of research cutting across basic studies of the virus, new treatments, and possible cure research.

In 2026, in the United States and 6 territories and freely associated states, there were 38,043 HIV diagnoses, more than half of which (52%) occurred among people living in the South.

The National HIV/AIDS Strategy for the United States (NHAS) sets bold targets for ending HIV in the United States by 2036, including a 75% reduction in new HIV infections by 2026 and a 90% reduction by 2036.

Significant funding for HIV testing and treatment is made available by initiatives like the President's Emergency Plan for AIDS Relief (PEPFAR) and the Ryan White HIV/AIDS Programme.

Industrial Development in China Push the HIV Diagnostics Market in China

Economic development in China's is quiet rapid and is accompanied by an equivalent strengthening of its diagnostic testing infrastructure by setting up reference laboratories, and thus access to these services such as early diagnosis and further treatment for HIV.

China has worked with a number of international organization such as the World Health Organization and UNAIDS, in particular to improve response to the HIV/AIDS epidemic.

With improved access to healthcare services, the rate of diagnosis and treatment of HIV has increased in China. Rising government attempts to fight the global pandemic through various reformatory measures in healthcare, coupled with growing public awareness of HIV/AIDS, are boosting demand for tests like HIV in China.

Due to the increased awareness, many people are coming forward to get themselves voluntarily tested for HIV, which is very helpful in early diagnosis and improves the treatment outcome.

Public awareness about HIV/AIDS has increased really fast in the past couple of years in China because of aggressive education campaigns and other public health initiatives. Often initiated by the government in conjunction with NGOs and international agencies, such campaigns stressed reducing stigma from HIV/AIDS, and testing regularly, particularly in high-risk groups.

Category-wise Insights

The section contains information about the leading segments in the industry. By product, the consumable segment is estimated to grow at a CAGR of 4.4% throughout 2036.

Consumables segment will dominate the HIV Diagnostics Market in terms of Value because of Increasing Adoption of Consumables in the Market

Product	Consumable
Value Share (2036)	55.6%

Consumables hold the largest chunk of the market share in terms of revenue among the product segment, holding a share of 55.6% in 2026. Some of the key factors attributing to the growth of the segment are, frequent testing for diagnosis of high-risk groups and rising awareness and uptake of public health screening programs.

There is growing dependency on consumables for various diagnostic procedures. Examples of consumables include test kits, reagents, and other consumables used in labs for the successful detection of HIV. As the world at large now focuses on the early diagnosis and effective management of HIV, the consumables are likely to be on a higher demand.

Home test kits are becoming more and more popular since they enable patients to test in the comfort of their home and maintains privacy. These tests also have a number of consumable parts such as buffer solutions, test cartridges or strips, and lancets for finger stick blood collection that are usually included in these kits.

The growing need for consumables in this market is partly attributed to the discretion and convenience that home testing kits provide.

Antibody Tests are Mostly Utilized in the HIV Diagnostics Market which leads to Major Market Share of Antibody Tests in HIV Diagnostics Industry

Test type	Antibody Tests
Value Share (2036)	42.5%

The antibody tests segment is forecast to account for a revenue of over USD 3,063.3 million in the HIV diagnostics market by 2036 end. Antibody tests are frequently used in prenatal screening, general healthcare screenings, and volunteer HIV testing campaigns, among other population screening initiatives.

These programmers’ dominance in the HIV diagnostics industry is partly due to the extensive use of antibody testing in them. Antibody tests cost less than combination and NAT. Their cost-effectiveness allows for wider accessibility and supports extensive screening initiatives.

Antibody tests represent the major share in the HIV Diagnostics Market since they are used in the detection of HIV infection. In the case of quick diagnostic tools, they usually come first into line due to their high accuracy, reliability, and ease of use.

Antibody testing has been widely adopted within clinical as well as home settings, effectively making them the top contributors of any particular segment by market size to the marketing division of the HIV diagnostics market.

Competitive Outlook

Important companies in the HIV testing business are making acquisitions and investments in cutting-edge facilities. In order to expand their footprint and further pierce the HIV diagnostics industry throughout several locations, major HIV diagnostics providers have also begun purchasing smaller competitors.

Scope of the Report

Metric	Value
Quantitative Units	USD 4.08 Billion to USD 8.42 Billion, at a CAGR of 7.50%
Market Definition	HIV diagnostics encompass in-vitro diagnostic products used for the detection, confirmation, and monitoring of human immunodeficiency virus infection. Product categories include consumables (reagent kits, rapid diagnostic tests, self-test kits), instruments (laboratory analyzers, point-of-care testing platforms), and software and services.
Segmentation	Product: Consumables, Instruments, Software & Services; Test Type: Antibody Tests, Viral Load Tests, CD4 Tests, Others; End User: Diagnostic Laboratories, Hospitals, Others
Regions Covered	North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East & Africa
Countries Covered	South Korea, Indonesia, Canada, France, Argentina, Poland, GCC Countries, and 40 plus countries
Key Companies Profiled	Siemens Healthineers, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Danaher Corporation, Thermo-Fisher Scientific Inc, Bristol-Myers Squibb Company, Janssen Global Services, LLC, Gilead Sciences, Inc., Merck & Co. Inc., QIAGEN, Apogee Flow Systems, Point Care
Forecast Period	2026 to 2036
Approach	Forecasting models apply a bottom-up methodology starting with regional utilization metrics and projecting adoption rates against demand drivers and regulatory frameworks.

Key Segments of HIV Diagnostics Industry

By Product:

In terms of product, the industry is divided into consumables, instruments, software & services.

By Test type:

In terms of indication, the industry is segregated into antibody tests, viral load tests, CD4 tests and others.

By End User:

The industry is classified by end user as diagnostic laboratories, hospitals and others.

By Region:

Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle East & Africa have been covered in the report.

Bibliography

• World Health Organization. (2025). Consolidated Guidelines on HIV Testing Services. WHO.
• USA Centers for Disease Control and Prevention. (2025). Revised Recommendations for HIV Testing. CDC.
• Joint United Nations Programme on HIV/AIDS. (2025). Global AIDS Update 2025. UNAIDS.
• USA Food and Drug Administration. (2025). Approved HIV Diagnostic Tests Database. FDA.
• Abbott Laboratories. (2025). Annual Report 2025: Diagnostics Division. Abbott.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with primary research documentation.